News Heart trial success will give Xarelto edge Xarelto aces outcomes trial and could have edge over Boehringer and BMS rivals.
News Bayer’s Stivarga fast-tracked for liver cancer review Bayer’s cancer treatment Stivarga has been granted priority review status by the FDA for use as a second line treatment of unresectable hepatocellular carcinoma (uHCC).
News Bayer teams with Leica for personalised cancer tests Collaboration will create tools capable of improving cancer treatment choices.
News BeyondSpring plans three-pronged attack on cancer The CEO of BeyondSpring said the company hopes to make its name with a new lung cancer drug and an innovative R&D strategy.
News MSD and Bayer launch big gamble on heart failure candidate Aims to recruit 4,900 patients to prove value in heart failure
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
